Description
Beta-Amyrin palmitate may release norepinephrine from newly synthesized pools, and thus, it may activate noradrenergic activity.
Beta-Amyrin palmitate, like mianserin and imipramine, reduces the duration of immobility of mice significantly in a dose-dependent manner (5, 10 and 20 mg kg-1);
(1)Beta-Amyrin palmitate or mianserin elicits a dose-related reduction in locomotor activity of mice and antagonizes locomotor stimulation induced by methamphetamine, imipramine increases locomotor activity and potentiates methamphetamine-induced hyperactivity;
(2)Beta-Amyrin palmitate shows no effect on reserpine-induced hypothermia, whilst mianserin (10 mg kg-1) and imipramine (10 and 20 mg kg-1) antagonizes the reserpine-induced effect;
(3)Beta-amyrin palmitate has similar properties in some respects to mianserin and might possess a sedative action.
Uses
β-Amyrin palmitate shows HMG-CoA reductase inhibition[1]. And β-Amyrin palmitate has anti-diabetes mellitus activity[2].
target
LDL | HMG-CoA Reductase | Adrenergic Receptor
References
[1] Maurya R, et al. β-Amyrin acetate and β-amyrin palmitate as antidyslipidemic agents from Wrightia tomentosa leaves.Phytomedicine. 2012;19(8-9):682-685. DOI:
10.1016/j.phymed.2012.03.013[2] Nair SA, et al. Promising anti-diabetes mellitus activity in rats of β-amyrin palmitate isolated from Hemidesmus indicus roots.Eur J Pharmacol. 2014;734:77-82. DOI:
10.1016/j.ejphar.2014.03.050
